Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sotevtamab + FOLFOX
- Development stage
- Phase 2
- Lead developer
- Alethia Biotherapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
**Sotevtamab + FOLFOX** is a combination regimen consisting of sotevtamab (AB-16B5), a monoclonal antibody developed as an epithelial-to-mesenchymal transition (EMT) inhibitor, and the FOLFOX chemotherapy regimen. FOLFOX consists of folinic acid (leucovorin), fluorouracil (5-FU), and oxaliplatin, and is widely used in the treatment of colorectal cancer. This combination is being investigated as a neoadjuvant therapy prior to surgical resection of colorectal cancer liver metastases. Sotevtamab is intended to inhibit EMT, a process involved in cancer cell invasion and metastasis, potentially increasing the efficacy of FOLFOX chemotherapy[1][2][3][7]. The regimen is currently being investigated in a phase II clinical trial.
- Brand names
- none known for this combination
- Other names
- none known for this combination
02
Targets
DNACLU (Clusterin)TS (Thymidylate synthase)
Beyond the preview
Go deeper on sotevtamab + FOLFOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sotevtamab + FOLFOX.